相关临床试验
24
3 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
2
8.3%
已完成
10
41.7%
尚未招募
1
4.2%
招募中
3
12.5%
终止
6
25.0%
Unknown
1
4.2%
撤回
1
4.2%
暂无批准数据
- Inovio Pharmaceuticals is awaiting an Oct. 30 FDA target action date for INO-3107, an investigational DNA medicine for HPV 6- and HPV 11-associated recurrent respiratory papillomatosis. - In the Phase I/II RRP-001 study, 72% of patients had a 50% to 100% surgery reduction in year one, rising to 86% in year two. - The BLA was filed under accelerated approval, but the FDA's file acceptance letter preliminarily questioned eligibility because an RRP product already holds full approval. - Inovio has completed pre-licensure inspections and expects labeling discussions in September, while a confirmatory trial design still requires FDA agreement.
- New benchmarking research from the Tufts Center for the Study of Drug Development, sponsored and commissioned by Syneos Health, examines how clinical sourcing models relate to trial performance and quality. - A Syneos Health white paper, Drug Development That Moves at the Speed of Change, builds on that research to consider what clinical development must become next. - The white paper outlines four connected dimensions of adaptive drug development: continuous evidence generation, more responsive regulatory engagement, combined AI, data and human expertise, and flexible operating models. - Syneos Health will present sessions on future-forward drug development and oversight at DPHARM 2026, including a fireside chat and panel on September 16.
- Spectrum Science has appointed Marie Emms, a 30-year healthcare communications veteran, as President of its clinical trial recruitment and retention business. - Emms previously led patient recruitment and engagement functions at Johnson & Johnson and Bristol Myers Squibb, bringing deep sponsor-side strategic expertise. - She will oversee the development of strategic patient engagement programs and drive innovation through Spectrum's AI-enabled MERIS™ platform. - Neil Weisman, former President of Spectrum Science Clinical, transitions to Chief Development Officer to focus on enterprise-level partnerships.
- The UK cardiovascular clinical trials market is forecast to grow from USD 507.8 million in 2025 to USD 892.2 million by 2033, reflecting a compound annual growth rate of 7.6%. - The NHS digital infrastructure encompassing approximately 67 million patient records is a key enabler for participant recruitment and real-world evidence generation in cardiovascular trials. - Approximately 7 million people in England live with cardiovascular conditions, with cardiovascular diseases accounting for about 26% of annual deaths, underscoring the urgent need for new interventions. - Novo Nordisk's January 2026 announcement to extend cardiovascular outcome studies in the UK highlights growing industry investment in obesity-related cardiovascular risk mitigation.
- The global women's clinical trials and CRO market is projected to grow from $9.9 billion in 2026 to $22.3 billion by 2036, at a CAGR of 8.5%. - Growth is driven by rising prevalence of women-predominant conditions, regulatory requirements for sex-specific safety evaluation, and precision medicine adoption. - Decentralized trial models are accelerating enrollment; Lindus Health's hybrid trials leveraged over 30 million EHRs to double enrollment speed versus traditional approaches. - U.S.-China tariff friction is disrupting biospecimen flows and central lab operations, prompting sponsors to shift recruitment toward CRO networks in India, Southeast Asia, and Europe.
- CareMetx and Syneos Health announced a strategic partnership to deliver a next-generation access model that provides faster, seamless support to providers and manufacturers for specialty medications. - The collaboration integrates CareMetx's proprietary technology platform with Syneos Health's Field Reimbursement Management teams and AI-powered healthcare intelligence platform, Kinetic. - The partnership aims to proactively address access challenges, streamline activation processes, and reduce integration time and burden for biopharma companies. - Together, the companies will offer manufacturers a more connected access model that reduces barriers and accelerates time to therapy for patients.
- Worldwide Clinical Trials has appointed Alistair Macdonald as Chief Executive Officer, effective immediately, succeeding Peter Benton who is retiring after 11 years of leadership. - Macdonald brings extensive clinical research industry experience, having previously served as CEO of Syneos Health where he scaled revenues from $1 billion to $5 billion. - The leadership transition occurs as Worldwide focuses on expanding capabilities and scaling globally with investments in technology and innovation to enhance customer service and quality. - Peter Benton will remain with the company as Senior Advisor to ensure seamless transition for employees and customers during this pivotal growth phase.
- CytoDyn has dosed the first patient in a Phase II clinical trial evaluating leronlimab, a CCR5 antagonist, in patients with relapsed/refractory microsatellite stable colorectal cancer. - The study is being conducted across eight clinical sites in partnership with Syneos Health, with Dr. Ben Weinberg from Georgetown University serving as lead principal investigator. - The trial builds on prior research showing potential clinical benefit of leronlimab in relapsed colorectal cancer and promising survival rates in metastatic triple-negative breast cancer. - Colorectal cancer represents a significant global health burden with approximately 1.9 million new cases and over 900,000 deaths annually worldwide according to WHO data.
- Merry Life Biomedical has launched a global Phase II clinical trial for TML-6, the first drug targeting the autolysosome pathway for Alzheimer's disease treatment. - The novel oral small molecule combines multiple mechanisms including anti-oxidative effects, autophagy function improvement, and anti-amyloid accumulation through a multi-target strategy. - The 12-month Phase II study will enroll 210 patients with mild cognitive impairment or mild dementia across 19 sites in the United States, Sweden, and Taiwan. - Phase I trials demonstrated excellent safety, tolerability, and pharmacokinetics at 100-200 mg doses in both healthy and elderly adults.
• The U.S. healthcare contract research organization market is expected to grow from $15.01 billion in 2025 to $29.68 billion by 2034, driven by increasing R&D investments and technological advancements. • Artificial intelligence integration is revolutionizing CRO operations through enhanced clinical trial design, automated data management, and improved patient recruitment, significantly boosting efficiency and productivity. • The preclinical CRO segment is projected to reach $4.66 billion by 2034, with an 8.2% CAGR, as pharmaceutical companies increasingly outsource specialized research services to reduce costs and accelerate drug development.
